Axovant Sciences (AXON) Cut to “Market Perform” at Cowen
Axovant Sciences (NASDAQ:AXON) was downgraded by equities research analysts at Cowen from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, The Fly reports.
AXON has been the topic of several other reports. BidaskClub downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Chardan Capital reissued a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a report on Saturday, September 23rd. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 target price on the stock in a report on Monday, October 9th. Robert W. Baird reissued a “hold” rating and issued a $6.00 target price on shares of Axovant Sciences in a report on Wednesday, November 1st. Finally, Oppenheimer reissued a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a report on Monday, September 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $14.14.
Axovant Sciences (AXON) opened at $2.27 on Friday. The company has a market capitalization of $243.42 and a P/E ratio of -0.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 1-year low of $2.23 and a 1-year high of $27.98.
A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Axovant Sciences by 968.5% in the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares during the last quarter. Capital Research Global Investors raised its position in Axovant Sciences by 21.8% in the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Janus Henderson Group PLC bought a new position in Axovant Sciences in the 2nd quarter worth approximately $47,854,000. OxFORD Asset Management LLP raised its position in Axovant Sciences by 842.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new position in Axovant Sciences in the 3rd quarter worth approximately $4,471,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.